Literature DB >> 10777146

Decreased HIV-associated T cell apoptosis by HIV protease inhibitors.

B N Phenix1, J B Angel, F Mandy, S Kravcik, K Parato, K A Chambers, K Gallicano, N Hawley-Foss, S Cassol, D W Cameron, A D Badley.   

Abstract

Antiretroviral treatment of patients infected with HIV results in improvements in CD4+ T cell number. Emerging evidence suggests that some of the improvements in CD4+ T cell number that occur in response to protease inhibitor (PI) therapy may not be accounted for solely by enhanced viral suppression, implying that PI may directly affect T cell survival. Since HIV T cell depletion is associated with enhanced apoptosis, we analyzed the effect of PIs on T cell apoptosis. In vitro treatment of peripheral blood lymphocytes (PBLs) from HIV-infected but untreated patients with reverse transcriptase inhibitors (RTIs) does not alter apoptosis, whereas PI treatment rapidly reduces CD4+ and CD8+ T cell apoptosis. In contrast, PI treatment does not alter apoptosis in PBL blasts from HIV-negative patients, or in Jurkat T cells. Consistent with this observation, 8 days of PI therapy in HIV-infected patients does not significantly alter plasma viremia, yet results in significant inhibition of CD4+ and CD8+ T cell apoptosis. The inhibitory effects of PI on apoptosis have implications concerning the treatment of HIV and its pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10777146     DOI: 10.1089/088922200308972

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  11 in total

1.  Expression of P-170 glycoprotein sensitizes lymphoblastoid CEM cells to mitochondria-mediated apoptosis.

Authors:  P Matarrese; U Testa; R Cauda; S Vella; L Gambardella; W Malorni
Journal:  Biochem J       Date:  2001-05-01       Impact factor: 3.857

Review 2.  HIV protease inhibitors impact on apoptosis.

Authors:  Stacey A Rizza; Andrew D Badley
Journal:  Med Chem       Date:  2008-01       Impact factor: 2.745

Review 3.  Antiretroviral treatment interruptions and risk of non-opportunistic diseases.

Authors:  Kenneth A Lichtenstein
Journal:  Curr HIV/AIDS Rep       Date:  2009-05       Impact factor: 5.071

Review 4.  New EMBO members' review: viral and bacterial proteins regulating apoptosis at the mitochondrial level.

Authors:  P Boya; B Roques; G Kroemer
Journal:  EMBO J       Date:  2001-08-15       Impact factor: 11.598

Review 5.  How I treat HIV-associated lymphoma.

Authors:  Kieron Dunleavy; Wyndham H Wilson
Journal:  Blood       Date:  2012-02-15       Impact factor: 22.113

6.  Effects of antiretroviral drugs on human immunodeficiency virus type 1-induced CD4(+) T-cell death.

Authors:  Jérôme Estaquier; Jean-Daniel Lelièvre; Frédéric Petit; Thomas Brunner; Laure Moutouh-De Parseval; Douglas D Richman; Jean Claude Ameisen; Jacques Corbeil
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

Review 7.  Nelfinavir: a review of its use in the management of HIV infection.

Authors:  Caroline M Perry; James E Frampton; Paul L McCormack; M Asif A Siddiqui; Risto S Cvetković
Journal:  Drugs       Date:  2005       Impact factor: 9.546

8.  Safety and Efficacy of Combination Antiretroviral Therapy in Human Immunodeficiency Virus-Infected Adults Undergoing Autologous or Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies.

Authors:  Christine Johnston; Robert Harrington; Rupali Jain; Joshua Schiffer; Hans-Peter Kiem; Ann Woolfrey
Journal:  Biol Blood Marrow Transplant       Date:  2015-08-08       Impact factor: 5.742

Review 9.  Yeast for virus research.

Authors:  Richard Yuqi Zhao
Journal:  Microb Cell       Date:  2017-09-18

Review 10.  Human immunodeficiency virus-1 (HIV-1)-mediated apoptosis: new therapeutic targets.

Authors:  Zukile Mbita; Rodney Hull; Zodwa Dlamini
Journal:  Viruses       Date:  2014-08-19       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.